Do analysts rate PTPI or CNSP?

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 273.13%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Petros Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is PTPI or CNSP more profitable?

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Petros Pharmaceuticals N/A -78.22% -23.50% CNS Pharmaceuticals N/A -238.68% -166.30%

Do analysts recommend VIRI or CNSP?

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 273.13%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Virios Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Virios Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, VIRI or CNSP?

Virios Therapeutics is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Virios Therapeutics N/A N/A -$5.30M -$0.27 N/A CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A

Is VIRI or CNSP more profitable?

Virios Therapeutics' return on equity of -130.33% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Virios Therapeutics N/A -130.33% -115.00% CNS Pharmaceuticals N/A -238.68% -166.30%

Which has preferable valuation and earnings, CNSP or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is CNSP or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets CNS Pharmaceuticals N/A -238.68% -166.30% Polyrizon N/A N/A N/A

Do analysts recommend IZTC or CNSP?

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 273.13%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Invizyne Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has stronger earnings and valuation, IZTC or CNSP?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Invizyne Technologies N/A N/A N/A N/A N/A CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A

Is IZTC or CNSP more profitable?

Invizyne Technologies' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Invizyne Technologies N/A N/A N/A CNS Pharmaceuticals N/A -238.68% -166.30%

CNS Pharmaceuticals (CNSP) Competitors

$5.36 -0.43 (-7.43%)

Closing price 04:00 PM Eastern

Extended Trading

$5.36 0.00 (-0.09%)

As of 06:05 PM Eastern

Compare

CNSP vs. PTPI, VIRI, PLRZ, KYNB, and IZTC

Should you buy CNS Pharmaceuticals stock or one of its competitors? MarketBeat compares CNS Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CNS Pharmaceuticals include Petros Pharmaceuticals (PTPI), Virios Therapeutics (VIRI), Polyrizon (PLRZ), Kyntra Bio (KYNB), and Invizyne Technologies (IZTC).

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Petros Pharmaceuticals (NASDAQ:PTPI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

CNS Pharmaceuticals has a consensus target price of $20.00, suggesting a potential upside of 273.13%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Petros Pharmaceuticals has a beta of 1.86, indicating that its share price is 86% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.05, indicating that its share price is 205% more volatile than the broader market.

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Petros Pharmaceuticals	N/A	-78.22%	-23.50%
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Petros Pharmaceuticals	$5.11M	0.02	-$8.16M	-$1.64	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

12.3% of Petros Pharmaceuticals shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 12.3% of Petros Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Petros Pharmaceuticals had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for Petros Pharmaceuticals and 0 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.98 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Petros Pharmaceuticals	Neutral
CNS Pharmaceuticals	Positive

Summary

Petros Pharmaceuticals beats CNS Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Virios Therapeutics?

Virios Therapeutics (NASDAQ:VIRI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, risk, earnings, profitability, valuation, dividends and institutional ownership.

In the previous week, CNS Pharmaceuticals' average media sentiment score of 0.98 beat Virios Therapeutics' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Virios Therapeutics	Neutral
CNS Pharmaceuticals	Positive

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 273.13%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Virios Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Virios Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Virios Therapeutics is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Virios Therapeutics	N/A	N/A	-$5.30M	-$0.27	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

Virios Therapeutics' return on equity of -130.33% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Virios Therapeutics	N/A	-130.33%	-115.00%
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

Virios Therapeutics has a beta of 1.58, meaning that its stock price is 58% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market.

9.1% of Virios Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 12.2% of Virios Therapeutics shares are owned by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CNS Pharmaceuticals beats Virios Therapeutics on 7 of the 12 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Polyrizon?

CNS Pharmaceuticals (NASDAQ:CNSP) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Polyrizon's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Polyrizon	N/A	N/A	N/A

CNS Pharmaceuticals currently has a consensus price target of $20.00, suggesting a potential upside of 273.13%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, CNS Pharmaceuticals' average media sentiment score of 0.98 beat Polyrizon's score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Polyrizon	Neutral

14.0% of CNS Pharmaceuticals shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

CNS Pharmaceuticals has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.5, suggesting that its stock price is 250% less volatile than the broader market.

Summary

CNS Pharmaceuticals beats Polyrizon on 7 of the 10 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Kyntra Bio?

CNS Pharmaceuticals (NASDAQ:CNSP) and Kyntra Bio (NASDAQ:KYNB) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, valuation, dividends, earnings and analyst recommendations.

Kyntra Bio has a net margin of 2,199.13% compared to CNS Pharmaceuticals' net margin of 0.00%. Kyntra Bio's return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Kyntra Bio	2,199.13%	N/A	-36.71%

CNS Pharmaceuticals currently has a consensus price target of $20.00, suggesting a potential upside of 273.13%. Kyntra Bio has a consensus price target of $32.50, suggesting a potential upside of 364.22%. Given Kyntra Bio's stronger consensus rating and higher possible upside, analysts plainly believe Kyntra Bio is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Kyntra Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

CNS Pharmaceuticals has a beta of 3.05, suggesting that its stock price is 205% more volatile than the broader market. Comparatively, Kyntra Bio has a beta of 1.02, suggesting that its stock price is 2% more volatile than the broader market.

In the previous week, Kyntra Bio had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for Kyntra Bio and 0 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.98 beat Kyntra Bio's score of 0.33 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Kyntra Bio	Neutral

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 72.7% of Kyntra Bio shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Kyntra Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Kyntra Bio has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Kyntra Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Kyntra Bio	$6.44M	4.40	$183.45M	$40.46	0.17

Summary

Kyntra Bio beats CNS Pharmaceuticals on 14 of the 16 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Invizyne Technologies?

Invizyne Technologies (NASDAQ:IZTC) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 273.13%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe CNS Pharmaceuticals is more favorable than Invizyne Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Invizyne Technologies' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Invizyne Technologies	N/A	N/A	N/A
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

In the previous week, Invizyne Technologies had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for Invizyne Technologies and 0 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 0.98 beat Invizyne Technologies' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Invizyne Technologies	Neutral
CNS Pharmaceuticals	Positive

Summary

CNS Pharmaceuticals beats Invizyne Technologies on 6 of the 9 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNSP vs. The Competition

Export

Metric	CNS Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$7.83M	$11.46B	$6.80B	$13.02B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-0.18	791.61	279.72	25.54
Price / Sales	N/A	947.20	648.69	115.96
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	0.74	10.44	11.12	6.36
Net Income	-$15.85M	$2.81B	$3.48B	$347.58M
7 Day Performance	5.72%	1.84%	2.58%	3.16%
1 Month Performance	5.72%	-3.13%	-2.79%	-2.06%
1 Year Performance	-28.63%	154.82%	64.28%	21.19%

CNS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNSP CNS Pharmaceuticals	3.9618 of 5 stars	$5.36 -7.4%	$20.00 +273.1%	-24.8%	$7.83M	N/A	N/A	5	Gap Down
PTPI Petros Pharmaceuticals	N/A	$0.00 flat	N/A	-90.4%	$125K	$5.11M	N/A	20
VIRI Virios Therapeutics	N/A	$1.53 +2.0%	N/A	-66.2%	$29.47M	N/A	N/A	5
PLRZ Polyrizon	0.4053 of 5 stars	$11.26 -19.8%	N/A	+61.9%	$29.26M	N/A	N/A	N/A
KYNB Kyntra Bio	3.7395 of 5 stars	$6.97 -1.1%	$32.50 +366.3%	N/A	$28.54M	$6.44M	0.17	570	News Coverage Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNSP) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, VIRI, PLRZ, KYNB, and IZTC

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Summary

How does CNS Pharmaceuticals compare to Virios Therapeutics?

Summary

How does CNS Pharmaceuticals compare to Polyrizon?

Summary

How does CNS Pharmaceuticals compare to Kyntra Bio?

Summary

How does CNS Pharmaceuticals compare to Invizyne Technologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, VIRI, PLRZ, KYNB, and IZTC

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Do analysts rate PTPI or CNSP?

Which has more volatility and risk, PTPI or CNSP?

Is PTPI or CNSP more profitable?

Which has stronger earnings & valuation, PTPI or CNSP?

Do institutionals & insiders have more ownership in PTPI or CNSP?

Does the media favor PTPI or CNSP?

Summary

How does CNS Pharmaceuticals compare to Virios Therapeutics?

Does the media prefer VIRI or CNSP?

Do analysts recommend VIRI or CNSP?

Which has better earnings & valuation, VIRI or CNSP?

Is VIRI or CNSP more profitable?

Which has more volatility and risk, VIRI or CNSP?

Do insiders & institutionals hold more shares of VIRI or CNSP?

Summary

How does CNS Pharmaceuticals compare to Polyrizon?

Is CNSP or PLRZ more profitable?

Do analysts recommend CNSP or PLRZ?

Does the media prefer CNSP or PLRZ?

Do institutionals and insiders have more ownership in CNSP or PLRZ?

Which has preferable valuation and earnings, CNSP or PLRZ?

Which has more risk & volatility, CNSP or PLRZ?

Summary

How does CNS Pharmaceuticals compare to Kyntra Bio?

Is CNSP or KYNB more profitable?

Do analysts prefer CNSP or KYNB?

Which has more risk and volatility, CNSP or KYNB?

Does the media prefer CNSP or KYNB?

Do insiders & institutionals have more ownership in CNSP or KYNB?

Which has better valuation & earnings, CNSP or KYNB?

Summary

How does CNS Pharmaceuticals compare to Invizyne Technologies?

Do institutionals & insiders hold more shares of IZTC or CNSP?

Which has stronger earnings and valuation, IZTC or CNSP?

Do analysts recommend IZTC or CNSP?

Is IZTC or CNSP more profitable?

Does the media favor IZTC or CNSP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools